Login to Your Account



American College of Rheumatology

HGSI's Phase III Benlysta Details Boost Confidence in Second Trial

By Trista Morrison


Wednesday, October 21, 2009
Detailed data from the first Phase III trial of Human Genome Sciences Inc.'s lupus drug Benlysta (belimumab) lived up to expectations, boosting analyst confidence in the outcome of a second Phase III trial to be revealed Nov. 2. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription